Concepedia

Publication | Open Access

Combined androgen blockade with bicalutamide for advanced prostate cancer

DOIFull Paper Access

194

Citations

18

References

2009

Year

Hideyuki Akaza, Shiro Hinotsu, Michiyuki Usami, Yoichi Arai, Hiroshi Kanetake, Seiji Naito, Yoshihiko Hirao
Cancer

Abstract

CAB with bicalutamide 80 mg offered a significant overall survival benefit compared with LHRH-A monotherapy without reducing tolerability in patients with locally advanced or metastatic prostate cancer.

References

YearCitations

Page 1